1. Novavax received full approval for Nuvaxovid vaccine from the FDA. 2. Stock surged 20% to $8.06 in premarket trading. 3. Nuvaxovid is the only protein-based Covid-19 vaccine in the U.S. 4. Approval triggers $175 million payment from Sanofi under license agreement. 5. FDA previously delayed approval amid health department layoffs.
Full FDA approval enhances market position against competitors like Pfizer and Moderna. Historical instances show FDA approvals can significantly boost stock prices, as seen with Moderna's rise post-approval.
The article discusses a significant regulatory milestone directly impacting stock performance and market perception. A successful approval is crucial for NVAX's financial recovery amidst previous setbacks.
The immediate market reaction is positive, but sustained growth depends on sales and competition. Past stock reactions post-approval indicate potential short-term volatility.